TRIMETAZIDIN-BIOKOM OF MV

General characteristics. Structure:

1 tablet with the modified release, coated, contains active agent of a trimetazidin of dihydrochloride 35 mg.

excipients: calcium hydrophosphate dihydrate, gipromelloz (gidroksipropilmetiltsellyuloza 4000), povidone (polyvinylpirrolidone low-molecular medical), silicon dioxide colloid (aerosil), magnesium stearate.

Structure of a cover: gipromelloza (gidroksipropilmetiltsellyuloza 4000), macrogoal (polyethyleneglycol 6000), titanium dioxide, ferrous oxide red.

Pharmacological properties:

Pharmacodynamics. Trimetazidin has anti-anginal, anti-hypoxemic effect. Directly influencing cardiomyocytes and neurons of a brain, optimizes their metabolism and function. The cytoprotective effect is caused by increase in energy potential, activation of oxidizing decarboxylation and rationalization of consumption of oxygen (strengthening of aerobic glycolysis and blockade of oxidation of fatty acids). Maintains contractility of a myocardium, prevents decrease in intracellular content of ATP and phosphocreatinine. In the conditions of acidosis normalizes functioning of ion channels, interferes with accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular maintenance of potassium ions. Reduces the intracellular acidosis and concentration of phosphates caused by ischemia of a myocardium and reperfusion. Interferes with the damaging action of free radicals, keeps integrity of cellular membranes, prevents activation of neutrophils in an ischemia zone, increases duration of electric potential, reduces a kreatinfosfokinaza exit from cells and expressiveness of ischemic injuries of a myocardium.

At stenocardia reduces the frequency of attacks (consumption of nitrates decreases), in 2 weeks of treatment tolerance to an exercise stress increases, differences of arterial pressure decrease. Hearing and results of vestibular tests at patients improves, dizziness and a sonitus decreases.

At vascular pathology of eyes recovers functional activity of a retina of an eye.

Pharmacokinetics. After administration of drug inside триметазидин it is quickly and almost completely absorbed from digestive tract. Bioavailability - 90%. Time of achievement of the maximum concentration in a blood plasma - 2 hours. The maximum concentration after a single dose of 35 mg of a trimetazidin about 55 ng/ml. Easily gets through gistogematichesky barriers. The elimination half-life (T1/2) makes 4,5-5 hours. Communication with proteins of a blood plasma - 16%. It is brought out of an organism by kidneys (about 60% in not changed look).

Indications to use:

- Coronary heart disease: prevention of attacks of stenocardia (in complex therapy);

 - Chorioretinal vascular disorders;

 - Dizzinesses of a vascular origin;

 - Cochleovestibular disturbances of the ischemic nature (sonitus, hearing disorder).

Route of administration and doses:

Inside, during food.

The recommended dosing mode - 2 tablets (70 mg) a day, in 2 receptions. A course of treatment according to the recommendation of the doctor.

Features of use:

Drug is not intended for stopping of attacks of stenocardia!

Against the background of treatment by drug patients to coronary heart disease have an essential reduction of daily need for nitrates.

Use of drug does not influence ability to driving and performance of work, mental and physical reactions demanding high speed.

Side effects:

Allergic reactions (skin itch). Seldom from digestive tract: gastralgia, nausea, vomiting; headache, feeling of strong heartbeat.

Interaction with other medicines:

There are no data.

Contraindications:

- Hypersensitivity to any component of drug;

- A renal failure (the clearance of creatinine is lower than 15 ml/min.);

- The expressed abnormal liver functions;

- Pregnancy;

- Breastfeeding period;

- Age up to 18 years (efficiency and safety are not established).

Overdose:

Now about cases of overdose of drug it was not reported.

Storage conditions:

In the dry, protected from light place, at a temperature not higher than 25 S. Hranit in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets with the modified release, coated, on 35 mg.

On 10 tablets in a blister strip packaging from a film of PVC and aluminum foil.

On 1, 2, 3, 4, 5 or 6 blister strip packagings together with the application instruction in a cardboard pack.